Previous Close | 1.5900 |
Open | 1.5600 |
Bid | 0.0000 x 1800 |
Ask | 0.0000 x 1000 |
Day's Range | 1.5600 - 1.7050 |
52 Week Range | 1.1300 - 7.3120 |
Volume | |
Avg. Volume | 102,954 |
Market Cap | 60.423M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 0.31 |
EPS (TTM) | 5.4500 |
Earnings Date | Mar 16, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.67 |
Subscribe to Yahoo Finance Plus to view Fair Value for CYT
LEXINGTON, Mass., January 19, 2023--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT) today announced the strategic prioritization of clinical development of CYT-0851, an investigational monocarboxylate transporter inhibitor, as a potential combination therapy for the treatment of ovarian cancer. The prioritization follows encouraging preliminary clinical activity in a small number of patients observed in the Phase 1 dose escalation cohort with CYT-0851 in combination with capecitabine in advan
LEXINGTON, Mass., November 07, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent operational highlights.
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...